AA
RCUS icon

AlphaCentric Advisors’s Arcus Biosciences RCUS Stock Holding History

AlphaCentric Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,100
Closed -$53K – 229
2020
Q3 		$53K Buy
3,100
+2,000
+182% +$44.7K 0.03% 101
2020
Q2 		$27K Buy
+1,100
New +$29.7K 0.02% 108

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCentric Advisors's RCUS Position: Q4 2020 in Review

AlphaCentric Advisors sold out of Arcus Biosciences (RCUS) in Q4 2020, closing a stake of 3,100 shares — an estimated $53K sold.

AlphaCentric Advisors first reported a position in RCUS in Q2 2020 and held it in 2 quarters. The position peaked at $53K in Q3 2020. 148 funds tracked by Wall St. Rank hold RCUS as of Q4 2020.

  • AlphaCentric Advisors reported no remaining Arcus Biosciences position as of Q4 2020 after selling out during the quarter.
  • AlphaCentric Advisors sold 3,100 Arcus Biosciences shares in Q4 2020, an estimated $53K.
  • AlphaCentric Advisors first reported a position in Arcus Biosciences in Q2 2020 and held it in 2 quarters.
  • AlphaCentric Advisors's Arcus Biosciences position peaked at $53K in Q3 2020.
  • 148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2020.

Based on AlphaCentric Advisors's 13F filing for Q4 2020, filed 11 Mar 2022.